

Karyopharm Therapeutics Inc.  
Form 8-K  
May 26, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): May 22, 2015**

**Karyopharm Therapeutics Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36167**  
**(Commission**  
  
**File Number)**

**26-3931704**  
**(I.R.S. Employer**  
  
**Identification No.)**

**85 Wells Avenue, 2<sup>nd</sup> Floor**

**Newton, MA**  
**(Address of principal executive offices)**

**02459**  
**(Zip Code)**

**Registrant's telephone number, including area code: (617) 658-0600**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

Karyopharm Therapeutics Inc. (the Company) held its Annual Meeting of Stockholders on May 22, 2015. The following is a summary of the matters voted on at that meeting.

1. The Company's stockholders elected Deepika R. Pakianathan Ph.D. and Kenneth E. Weg as class II directors to serve until the 2018 Annual Meeting of Stockholders, each such director to hold office until his successor has been duly elected and qualified. The results of the stockholders' vote with respect to the election of such class II directors were as follows:

	<b>Votes For</b>	<b>Votes Withheld</b>	<b>Broker Non-Votes</b>
Deepika R. Pakianathan, Ph.D.	25,542,732	1,647,741	3,135,519
Kenneth E. Weg	27,162,353	28,120	3,135,519

2. The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the current fiscal year. The results of the stockholders' vote with respect to such ratification were as follows:

<b>Votes For</b>	<b>Votes Against</b>	<b>Votes Abstaining</b>	<b>Broker Non-Votes</b>
30,162,360	153,234	10,398	0

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KARYOPHARM THERAPEUTICS INC.

Date: May 26, 2015

By: /s/ Christopher B. Primiano  
Christopher B. Primiano  
Vice President, Corporate Development, General  
Counsel and Secretary